Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade F 24.49 1.45% 0.35
MYGN closed up 1.45 percent on Friday, May 24, 2019, on 79 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MYGN trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.45%
Expansion Breakdown Bearish Swing Setup 1.45%
Reversal New Lows Setup Bearish Swing Setup 1.45%
New 52 Week Low Weakness 1.45%
Wide Bands Range Expansion 1.45%
Oversold Stochastic Weakness 1.45%

Older signals for MYGN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Ovarian Cancer Medical Genetics Diagnostic Tests Pancreatic Cancer Biomarkers Chemical Pathology Personalized Medicine
Is MYGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 50.44
52 Week Low 23.93
Average Volume 846,584
200-Day Moving Average 35.1001
50-Day Moving Average 31.2
20-Day Moving Average 28.58
10-Day Moving Average 25.678
Average True Range 1.2178
ADX 36.96
+DI 11.2381
-DI 39.7274
Chandelier Exit (Long, 3 ATRs ) 31.5866
Chandelier Exit (Short, 3 ATRs ) 27.5834
Upper Bollinger Band 35.7205
Lower Bollinger Band 21.4395
Percent B (%b) 0.21
BandWidth 49.968509
MACD Line -2.0251
MACD Signal Line -1.6349
MACD Histogram -0.3901
Fundamentals Value
Market Cap 1.68 Billion
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 76.53
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.74
Resistance 3 (R3) 25.79 25.44 25.53
Resistance 2 (R2) 25.44 25.12 25.41 25.46
Resistance 1 (R1) 24.96 24.92 25.20 24.91 25.39
Pivot Point 24.61 24.61 24.73 24.58 24.61
Support 1 (S1) 24.13 24.29 24.37 24.08 23.59
Support 2 (S2) 23.78 24.09 23.75 23.52
Support 3 (S3) 23.30 23.78 23.45
Support 4 (S4) 23.25